Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis...

by Benson G, Morton T, Thomas H, Lee XY
Published 2021-01-01

Systematic review: treatment pattern and clinical effectiveness and safety of pharmaceutical therapies for Crohn’s disease in Europe

by Lelli F, Nuhoho S, Lee XY, Xu WW
Published 2016-10-01

Real-world utilities and health-related quality-of-life data in hemophilia patients in France and the United Kingdom

by Carroll L, Benson G, Lambert J, Benmedjahed K, Zak M, Lee XY
Published 2019-06-01

Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII

by Kearney S, Raffini LJ, Pham TP, Lee XY, von Mackensen S, Landorph A, Takedani H, Oldenburg J
Published 2019-04-01